| Identification | Back Directory | [Name]
3-hydroxypropanoic acid | [CAS]
75898-90-7 | [Synonyms]
Unii-I229274Y5b
Amrinone lactate
Inamrinone lactate
DOSIONJFGDSKCQ-UHFFFAOYSA-N
3-amino-5-pyridin-4-yl-1H-pyridin-2-one
(3,4'-Bipyridin)-6(1H)-one, 5-amino-, 3-hydroxypropanoate
3-Hydroxypropanoic acid compd. with 5-amino-(3,4'-bipyridin)-6(1H)-one
Propanoic acid, 3-hydroxy-, compd. with 5-amino-(3,4'-bipyridin)-6(1H)-one | [Molecular Formula]
C13H15N3O4 | [MDL Number]
MFCD01742776 | [MOL File]
75898-90-7.mol |
| Hazard Information | Back Directory | [Uses]
Amrinone lactate is a positive inotropic-vasodilator agent. Amrinone lactate is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone lactate is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent[1][2][3]. | [Veterinary Drugs and Treatments]
Inamrinone is considered a second line agent for the short-term
management
of CHF. It was originally called amrinone, but was
changed to inamrinone presumably to avoid confusion with
amiodarone. | [References]
[1] A A Alousi, et al. The Beneficial Effect of Amrinone on Acute Drug-Induced Heart Failure in the Anaesthetised Dog. Cardiovasc Res. 1985 Aug;19(8):483-94. DOI:10.1093/cvr/19.8.483
[2] S Ichioka, et al. Clinical Use of Amrinone (A Selective Phosphodiesterase III Inhibitor) in Reconstructive Surgery. Plast Reconstr Surg. 2001 Dec;108(7):1931-7. DOI:10.1097/00006534-200112000-00013
[3] T H LeJemtel, et al. Amrinone: A New Non-Glycosidic, Non-Adrenergic Cardiotonic Agent Effective in the Treatment of Intractable Myocardial Failure in Man. Circulation. 1979 Jun;59(6):1098-104. DOI:10.1161/01.cir.59.6.1098
[4] M Hachisu, et al. [Effects of Amrinone, an Inhibitor of c-AMP-specific Phosphodiesterases, on Neointimal Hyperplasia After Balloon Injury in Rats]. Nihon Yakurigaku Zasshi. 1998 Oct;112(4):267-74. DOI:10.1254/fpj.112.267 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|